___

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265.
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe bymorphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724.
• Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed Sternbergcells in lymphocyte predominant Hodgkin diseasere present clonal populations of germinal center- derived tumor B cells. ProcNatl Acad Sci USA. 1997;94:9337. 4. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin'sdisease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453.
• Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997;337:459
• Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151.
• Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71:2062.
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the EuropeanTask Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776.
• Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Grouptrials. J ClinOncol. 2005;23:5739.
• National Comprehensive Cancer Network (NCCN 2.2015). NCCN
• http://www.nccn.org/professionals/physician_gls/f_guidelines. asp
• Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte- predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136.
• Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221.
• Nogová L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte- predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683.
• Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancerand Groupe d'Etudedes Lymphomes de l'Adultevery favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94:1731.
• Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior toradiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J ClinOncol. 2007;25:3495.
• Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancerand Leukaemia Groupreport. Br J Haematol. 2007;138:761.
• Fanale MA, Lai CM, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:2812.
• Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J ClinOncol. 1997;15:3060.
• Karuturi M, Hosing C, Fanale M, et al. High- dosechemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19:991. in
• oncology. 11. 12. 13. 14. 15. 16. 17. 18. 19. http://edergi.cbu.edu.tr/ojs/index.php/cbusbed isimli
• yazarın CBU-SBED başlıklı eseri bu Creative Commons Alıntı-Gayriticari lisanslanmıştır. Lisansı ile